Skip to main content
MarketStoryBook

LLY in “America Imports the World's Drug Prices”

Eli Lilly and Company

Bear sideStableExposure: not rated yet

Its premium-priced, high-growth drug portfolio has substantial earnings sensitivity to lower US benchmark prices.

LLY impact map — “America Imports the World's Drug Prices”

How this story travels from the headline to LLY’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.

Loading LLY impact map…

Price history, marked with story events

Oct 8, 2025 – Oct 9, 2026 · 250 sessions

Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions

Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…

Full story

America Imports the World's Drug Prices

US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.

BEAR side — Its premium-priced, high-growth drug portfolio has substantial earnings sensitivity to lower US benchmark prices.

Read the full America Imports the World's Drug Prices story

Bull side

2 stories
  • GLP-1 Eats Everything

    LLY in “GLP-1 Eats Everything”

    FadingExposure: not rated yet

    Appetite suppression as a macro variable.

    Supply-constrained franchise with pricing power.

  • China Becomes Pharma's Global R&D Engine

    LLY in “China Becomes Pharma's Global R&D Engine”

    FadingExposure: not rated yet

    Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.

    Lilly can supplement its internal pipeline at attractive speed and cost through deals such as its acquisition of ex-China rights to Hengrui's investigational incretin program.

Bear side

1 story
  • LLY in “America Imports the World's Drug Prices”

    StableExposure: not rated yet
    Viewing

    US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.

    Its premium-priced, high-growth drug portfolio has substantial earnings sensitivity to lower US benchmark prices.